Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Détails

ID Serval
serval:BIB_6F6B17DDC9A3
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Périodique
Nature
Auteur⸱e⸱s
Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B.
ISSN
1476-4687 (Electronic)
ISSN-L
0028-0836
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
461
Numéro
7262
Pages
399-401
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN-alpha-2b) or -alpha-2a (PegIFN-alpha-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African ancestry. In addition to limited efficacy, treatment is often poorly tolerated because of side effects that prevent some patients from completing therapy. For these reasons, identification of the determinants of response to treatment is a high priority. Here we report that a genetic polymorphism near the IL28B gene, encoding interferon-lambda-3 (IFN-lambda-3), is associated with an approximately twofold change in response to treatment, both among patients of European ancestry (P = 1.06 x 10(-25)) and African-Americans (P = 2.06 x 10(-3)). Because the genotype leading to better response is in substantially greater frequency in European than African populations, this genetic polymorphism also explains approximately half of the difference in response rates between African-Americans and patients of European ancestry.
Mots-clé
African Americans/genetics, Chromosomes, Human, Pair 19/genetics, Clinical Trials as Topic, Europe/ethnology, Far East/ethnology, Gene Frequency, Genetic Variation/genetics, Genome, Human/genetics, Genome-Wide Association Study, Genotype, Hepacivirus/drug effects, Hepatitis C, Chronic/drug therapy, Hepatitis C, Chronic/ethnology, Hispanic Americans/genetics, Humans, Interferon-alpha/adverse effects, Interferon-alpha/pharmacology, Interleukins/genetics, Pharmacogenetics, Polyethylene Glycols/adverse effects, Polyethylene Glycols/pharmacology, Polymorphism, Single Nucleotide/genetics, Recombinant Proteins, Viral Load
Pubmed
Web of science
Création de la notice
01/03/2012 16:14
Dernière modification de la notice
20/08/2019 15:28
Données d'usage